Scientific Poster
IQVIA publications in ASCO21 virtual science program
May 27, 2021

The American Society of Clinical Oncology 2021 Annual Meeting features 21 abstracts from IQVIA demonstrating Connected Intelligence solutions spanning precision medicine, immuno-oncology trials, and real world insights during a global pandemic.

Contact Us

See below for more ASCO21 abstracts from IQVIA authors.  

Breast cancer survivorship and level of institutional involvement utilizing integrative oncology.

Publication-Only Abstracts: Health Services Research and Quality Improvement

View Abstract

 

Awareness, perceptions, and usage of whole person integrative oncology practices: Similarities and differences between breast cancer patients and oncologists.

Publication-Only Abstracts: Symptoms and Survivorship

View Abstract

 

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

Oral Abstract Session: Breast Cancer—Metastatic

View Abstract

 

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.

Poster Session: Developmental Therapeutics—Immunotherapy

View Abstract

 

An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes.

Poster Session: Gynecologic Cancer

View Abstract

 

Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.

Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

View Abstract

 

Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥50%: Results from EMPOWER-Lung 1 study.

Poster Session: Lung Cancer—Non-Small Cell Metastatic

View Abstract

 

Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial.

Poster Session: Melanoma/Skin Cancers

View Abstract

 

The impact of cancer-related diarrhea on changes in cancer therapy patterns.

Poster Session: Symptoms and Survivorship

View Abstract

 

Oncology clinical research landscape in Middle East and North Africa (MENA) region: Challenges and proposed solutions.

Publication-Only Abstracts: Care Delivery and Regulatory Policy

View Abstract

 

OEN: Multi-center, international, real-world evidence studies performed using health records without data pooling—The use of a common data model and shared analytical methods.

Publication-Only Abstracts: Care Delivery and Regulatory Policy

View Abstract

 

Phase I study of BJ-001, a tumor-targeting interleukin-15 fusion protein, in patients with solid tumor.

Publication-Only Abstracts: Developmental Therapeutics—Immunotherapy

View Abstract

 

Cost-effectiveness of atezolizumab monotherapy versus pembrolizumab monotherapy for first-line (1L) treatment of metastatic non-small cell lung cancer (mNSCLC).

Publication-Only Abstracts: Health Services Research and Quality Improvement

View Abstract

 

Characterizing unplanned resource utilization associated with cancer-related diarrhea.

Publication-Only Abstracts: Health Services Research and Quality Improvement

View Abstract

 

Healthcare utilization and costs associated with cancer-related diarrhea.

Publication-Only Abstracts: Health Services Research and Quality Improvement

View Abstract

 

Incidence of pneumonitis among limited-stage small cell lung cancer patients exposed to concurrent chemoradiation: A systematic literature review and meta-analysis.

Publication-Only Abstracts: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

View Abstract

 

Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A meta-analysis.

Publication-Only Abstracts: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

View Abstract

 

Psychometric properties of patient reported outcome (PRO) instruments in patients with small cell lung cancer (SCLC) in RESILIENT part 1.

Publication-Only Abstracts: Symptoms and Survivorship

View Abstract